Ainos Inc. Warrants (AIMDW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Ainos, Inc. (NASDAQ:AIMDW) Sees Significant Decrease in Short Interest
Ainos, Inc. (NASDAQ: AIMDW - Get Free Report) was the recipient of a significant decline in short interest in February. As of February 27th, there was short interest totaling 3,421 shares, a decline of 23.0% from the February 12th total of 4,440 shares. Based on an average trading volume of 2,624 shares, the days-to-cover ratio is
Ainos Inc. Warrants Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 11,050 | $2,045 | $1,657.5 | -$387.5 | -18.95% |
Ainos Inc. Warrants (AIMDW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ainos Inc. Warrants ever had a stock split?
Ainos Inc. Warrants Profile
| Biotechnology Industry | Healthcare Sector | Chun-Hsien Tsai CEO | NASDAQ (CM) Exchange | 00902F113 CUSIP |
| US Country | 44 Employees | - Last Dividend | - Last Split | 4 Nov 2013 IPO Date |
Overview
Ainos, Inc. is a healthcare company that has dedicated its efforts towards the advancement of medical technologies specifically designed for point-of-care testing and the provision of safe, novel medical treatments for various disease indications. The enterprise emerged from its previous identity as Amarillo Biosciences, Inc., undergoing a name change to Ainos, Inc. in May 2021, signaling a new phase in its journey. This transformation reflects a broadened scope and ambition in addressing healthcare challenges through innovative solutions. Having been incorporated back in 1984, Ainos has its operational base established in San Diego, California, positioning it well within one of the United States' biotech hotspots, which allows for better integration into the industry's innovative core.
Products and Services
- COVID-19 Antigen Rapid Test Kit and Ainos' Cloud-Based Test Management App: This offering consists of an antigen rapid test kit, a personal application, and an enterprise app. Together, they provide an integrated solution for managing COVID-19 testing at both individual and organizational levels, leveraging cloud technology for efficiency and scalability.
- COVID-19 Nucleic Acid Test: A diagnostic tool designed for the detection of COVID-19, utilizing the sensitivity and specificity advantages of nucleic acid testing methodologies to ensure reliable results.
- Volatile Organic Compounds Point-of-Care Testing: Ainos develops technology for the detection of volatile organic compounds (VOCs) in a point-of-care setting, facilitating the early diagnosis of diseases through non-invasive means.
- Very Low-Dose Oral Interferon Alpha: This involves a low-dose oral formulation of interferon alpha, harnessing IFN-alpha's broad treatment applications in a potentially safer and patient-friendly manner. The approach suggests an innovative path in combating various diseases by modulating the immune response.
- Synthetic RNA: Ainos is also pioneering in the realm of SRNA (Synthetic RNA) technology platform in Taiwan, aiming at harnessing the potential of synthetic RNA in gene editing and therapy, thereby opening new avenues for treatment modalities.
- Additional Offerings: The company's portfolio extends beyond the aforementioned with products aimed at women's health, pneumonia treatment, and the development of unique tools such as the Ainos Pen and AI Nose. These developments signify Ainos' diversified approach towards tackling healthcare challenges with technology-driven solutions.
